The United Laboratories International Holdings Stock Value
The United Laboratories International Holdings Company Info
EPS Growth 5Y
20,02%
Market Cap
HK$19,91 B
Long-Term Debt
HK$3,20 B
Quarterly earnings
05/29/2026 (E)
Dividend
HK$0,48
Dividend Yield
4,74%
Founded
1990
Industry
Country
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
HK$16,18
60.36%
Last Update: 04/11/2026
Analysts: 8
Highest Price Target HK$20,00
Average Price Target HK$16,18
Lowest Price Target HK$12,80
In the last five quarters, The United Laboratories International Holdings’s Price Target has risen from HK$9,52 to HK$12,11 - a 27,21% increase. Seven analysts predict that The United Laboratories International Holdings’s share price will increase in the coming year, reaching HK$16,18. This would represent an increase of 60,36%.
Top growth stocks in the health care sector (5Y.)
What does The United Laboratories International Holdings do?
The United Laboratories International Holdings Limited is a company in the pharmaceutical industry, primarily engaged in the research, development, manufacturing, and distribution of a diversified range of pharmaceutical products.
Business Segments
The company three major business segments including Intermediate Products, Bulk Medicine, and Finished Products.
Intermediate Products
This segment focuses on the production and sale of active pharmaceutical ingredients, particularly 6-APA product...
The United Laboratories International Holdings Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Industry Revenues:**
- **Pharmaceutical Products:** approx. 70%
- **Animal Health:** approx. 20%
- **Other Business Areas:** approx. 10%
**TOP 3 Markets:**
- **China:** approx. 60%
- **Southeast Asia:** approx. 20%
- **Europe:** approx. 10%
The United Laboratories International Holdings Limited...
At which locations are the company’s products manufactured?
**Production Sites:** China
The United Laboratories International Holdings Limited produces the majority of its products in China. The company has several production facilities in different regions of China that specialize in the manufacturing of pharmaceutical products and active ingredients. This...
What strategy does The United Laboratories International Holdings pursue for future growth?
**Revenue Growth:** Estimated 8-10% annually (2026)
**Focus on R&D Investments:** Increase by 15% (2025)
The United Laboratories International Holdings Limited pursues a growth strategy that heavily emphasizes research and development (R&D). The company has significantly increased its inve...
Which raw materials are imported and from which countries?
**Main raw materials:** Antibiotic active ingredients, chemicals for pharmaceutical products
**Countries of origin:** China, India, Germany
The United Laboratories International Holdings Limited mainly imports active ingredients and chemicals needed for the production of antibiotics and other pha...
How strong is the company’s competitive advantage?
**Market share in China:** 5.2% (2025, estimated)
**R&D expenses:** 8.5% of revenue (2025)
**EBITDA margin:** 18.7% (2025)
The United Laboratories International Holdings Limited has a significant competitive advantage in the Chinese pharmaceutical market, especially through its strong prese...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Estimated 35% (2026)
**Insider Buys/Sells:** No significant transactions reported (2026)
The institutional investor share in The United Laboratories International Holdings Limited is estimated to be around 35%. This suggests that a significant number of shares ar...
What percentage market share does The United Laboratories International Holdings have?
**Market share of The United Laboratories International Holdings Limited:** Estimated 5% (2026)
**Top competitors and their market shares:**
1. **Sinopharm Group Co. Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co. Ltd.:** 12%
3. **CSPC Pharmaceutical Group Limited:** 10%
4. **China Resources...
Is The United Laboratories International Holdings stock currently a good investment?
**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Research and Development Ratio:** 5.7% of revenue (2025)
The United Laboratories International Holdings Limited recorded a solid revenue growth of 8.5% in 2025, indicating stable demand for its pharmaceutical products. The profit gro...
Does The United Laboratories International Holdings pay a dividend – and how reliable is the payout?
**Dividend Yield:** Estimate 3.5% (2026)
The United Laboratories International Holdings Limited has regularly paid out dividends in the past. The dividend yield is estimated to be around 3.5% for 2026, based on the latest available financial reports and market analyses.
The reliability of dividend...
